The rise of Viagra initially sparked a boom for pharma, nevertheless recent developments present a uncertain outlook for investors. Generic alternatives are eroding revenue, and persistent patent challenges add further https://graysonuobe750733.alltdesign.com/the-blue-pill-and-big-pharma-a-risky-play-59902667